Physician profile
Nelson A Prager
NPI 1952397895
$16,049.24
in general payments reported to CMS, 2019-2025
28 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $990 · 2021: $2,660 · 2022: $2,881 · 2023: $2,851 · 2024: $2,666 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,283.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $11,837.25 | 2019-2025 | Ensite, Viewmate, Tacticath Ablation Catheter, Sensor Enabled |
| Boston Scientific Corporation | $1,192.13 | 2019-2023 | Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $538.13 | 2019-2025 | |
| Edwards Lifesciences Corporation | $369.21 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Heartflow, INC. | $293.35 | 2024-2025 | |
| Penumbra, INC. | $173.33 | 2025 | Indigo System |
| Cleerly, INC. | $161.13 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Impulse Dynamics (USA) INC. | $159.70 | 2021-2023 | Optimizer |
| Cvrx, INC. | $146.30 | 2023 | Barostim Neo System |
| Amgen INC. | $142.01 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $136.72 | 2022-2025 | (Ck4) Mcot, Extended Holter |
| Pfizer INC. | $131.47 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $117.07 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $88.32 | 2022-2023 | Verquvo |
| Cardiva Medical, INC. | $67.89 | 2021-2024 | Optowire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $67.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $65.67 | 2023-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.17 | 2019-2022 | |
| Medtronic, INC. | $53.24 | 2021-2025 | Pulseselect |
| Biosense Webster, INC. | $50.97 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.11 | 2021-2025 | |
| Preventice Services, LLC | $35.54 | 2019 | |
| Esperion Therapeutics, INC. | $25.06 | 2021 | |
| Siemens Medical Solutions USA, INC. | $24.92 | 2021 | |
| Abiomed | $20.32 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $19.64 | 2021 | |
| Ethicon US, LLC | $15.35 | 2025 | Vistaseal |
| Astrazeneca Pharmaceuticals LP | $14.66 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Prager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.